Abivax S.A. (ABVX)
Healthcare
Biotechnology
124.90 $
+0.5%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns Abivax S.A. (ABVX)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 77.0% of the shares are freely tradable; institutional investors hold 70.6%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
70.6%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
0.0%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
77.0%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
4.7%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
87Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| TCG Crossover Management, LLC | 7.44 | 6,481,085 | -8.9 | 03/31/2026 |
| UBS Group AG | 5.22 | 4,547,406 | +2.8 | 03/31/2026 |
| Darwin Global Management, Ltd. | 3.98 | 3,468,657 | +9.1 | 03/31/2026 |
| Morgan Stanley - Brokerage Accounts | 1.96 | 1,704,958 | -45.9 | 03/31/2026 |
| Vestal Point Capital LP | 1.72 | 1,500,000 | -21.1 | 03/31/2026 |
| Caligan Partners LP | 1.68 | 1,461,924 | +0.7 | 03/31/2026 |
| ADAR1 Capital Management LLC | 1.60 | 1,394,019 | +5.8 | 03/31/2026 |
| Westfield Capital Management Company, L.P. | 1.52 | 1,322,938 | +31.0 | 03/31/2026 |
| FMR Inc | 1.48 | 1,286,373 | -5.8 | 03/31/2026 |
| Helikon Investments Ltd | 1.16 | 1,013,324 | +0.0 | 03/31/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.